Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

Andrew Lukas Yin, David Hachuel, John P Pollak, Ellen J Scherl, Deborah Estrin, Andrew Lukas Yin, David Hachuel, John P Pollak, Ellen J Scherl, Deborah Estrin

Abstract

Background: Digital health is poised to transform health care and redefine personalized health. As Internet and mobile phone usage increases, as technology develops new ways to collect data, and as clinical guidelines change, all areas of medicine face new challenges and opportunities. Inflammatory bowel disease (IBD) is one of many chronic diseases that may benefit from these advances in digital health. This review intends to lay a foundation for clinicians and technologists to understand future directions and opportunities together.

Objective: This review covers mobile health apps that have been used in IBD, how they have fit into a clinical care framework, and the challenges that clinicians and technologists face in approaching future opportunities.

Methods: We searched PubMed, Scopus, and ClinicalTrials.gov to identify mobile apps that have been studied and were published in the literature from January 1, 2010, to April 19, 2019. The search terms were ("mobile health" OR "eHealth" OR "digital health" OR "smart phone" OR "mobile app" OR "mobile applications" OR "mHealth" OR "smartphones") AND ("IBD" OR "Inflammatory bowel disease" OR "Crohn's Disease" (CD) OR "Ulcerative Colitis" (UC) OR "UC" OR "CD"), followed by further analysis of citations from the results. We searched the Apple iTunes app store to identify a limited selection of commercial apps to include for discussion.

Results: A total of 68 articles met the inclusion criteria. A total of 11 digital health apps were identified in the literature and 4 commercial apps were selected to be described in this review. While most apps have some educational component, the majority of apps focus on eliciting patient-reported outcomes related to disease activity, and a few are for treatment management. Significant benefits have been seen in trials relating to education, quality of life, quality of care, treatment adherence, and medication management. No studies have reported a negative impact on any of the above. There are mixed results in terms of effects on office visits and follow-up.

Conclusions: While studies have shown that digital health can fit into, complement, and improve the standard clinical care of patients with IBD, there is a need for further validation and improvement, from both a clinical and patient perspective. Exploring new research methods, like microrandomized trials, may allow for more implementation of technology and rapid advancement of knowledge. New technologies that can objectively and seamlessly capture remote data, as well as complement the clinical shift from symptom-based to inflammation-based care, will help the clinical and health technology communities to understand the full potential of digital health in the care of IBD and other chronic illnesses.

Keywords: Crohn’s disease; digital health; eHealth; inflammatory bowel disease; mHealth; mobile health; mobile technology; review; smartphone; ulcerative colitis.

Conflict of interest statement

Conflicts of Interest: DH is cofounder and CEO of augGI Technologies Inc. EJS receives research funding from the CCFA and the UCSF-CCFA Clinical Research Alliance and also consults with the CCFA. The remaining authors have no conflicts of interest to declare.

©Andrew Lukas Yin, David Hachuel, John P Pollak, Ellen J Scherl, Deborah Estrin. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 19.08.2019.

Figures

Figure 1
Figure 1
Selection process for articles about inflammatory bowel disease (IBD) digital health apps.

References

    1. The Mobile Economy: 2019. London, UK: GSM Association; 2019. [2019-07-29]. .
    1. Fox S, Duggan M. Pew Research Center. Washington, DC: Pew Internet & American Life Project; 2013. Jan 15, [2019-07-29]. Health online 2013
    1. Makovsky. 2015. Feb 24, [2019-04-30]. Fifth annual "Pulse of Online Health" Survey finds 66% of Americans eager to leverage digital tools to manage personal health
    1. mHealth App Economics 2017: Current Status and Future Trends in Mobile Health. Berlin, Germany: Research2Guidance; 2017. Nov, [2019-04-30]. 325,000 mobile health apps available in 2017: Android now the leading mHealth platform
    1. Con D, Jackson B, Gray K, De Cruz P. eHealth for inflammatory bowel disease self-management: The patient perspective. Scand J Gastroenterol. 2017 Sep;52(9):973–980. doi: 10.1080/00365521.2017.1333625.
    1. Foster KR, Callans DJ. Smartphone apps meet evidence-based medicine: The future of medicine may (or may not) be in your smartphone. IEEE Pulse. 2017;8(6):34–39. doi: 10.1109/MPUL.2017.2750783.
    1. Murray E, Hekler EB, Andersson G, Collins LM, Doherty A, Hollis C, Rivera DE, West R, Wyatt JC. Evaluating digital health interventions: Key questions and approaches. Am J Prev Med. 2016 Nov;51(5):843–851. doi: 10.1016/j.amepre.2016.06.008.
    1. Patrick K, Hekler EB, Estrin D, Mohr DC, Riper H, Crane D, Godino J, Riley WT. The pace of technologic change: Implications for digital health behavior intervention research. Am J Prev Med. 2016 Nov;51(5):816–824. doi: 10.1016/j.amepre.2016.05.001.
    1. Bradway M, Ribu L, Hartvigsen G, Årsand E. The evolution of clinicians’ preparedness for mHealth use (2013-2017) and current barriers. Proceedings from the 16th Scandinavian Conference on Health Informatics 2018; 16th Scandinavian Conference on Health Informatics 2018; August 28-29, 2018; Aalborg, Denmark. Linköping, Sweden: Linköping University Electronic Press; 2018. pp. 45–50.
    1. Kane JM. Technology-based interventions in health care. Epidemiol Psychiatr Sci. 2014 Dec;23(4):323–326. doi: 10.1017/S2045796014000444.
    1. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults: Estimates from the National Health Interview Survey, 2010. Prev Chronic Dis. 2013 Apr 25;10:e65. doi: 10.5888/pcd10.120203.
    1. Burttorff C, Ruder R, Bauman M. Multiple Chronic Conditions in the United States. Santa Monica, CA: The RAND Corporation; 2017. [2019-04-30]. .
    1. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW, Kaplan GG. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012 Jan;142(1):46–54.e42; quiz e30. doi: 10.1053/j.gastro.2011.10.001.
    1. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV. Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017 Jun;15(6):857–863. doi: 10.1016/j.cgh.2016.10.039.
    1. Feagins LA, Iqbal R, Spechler SJ. Case-control study of factors that trigger inflammatory bowel disease flares. World J Gastroenterol. 2014 Apr 21;20(15):4329–4334. doi: 10.3748/wjg.v20.i15.4329.
    1. Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005 Oct;11(10):909–918. doi: 10.1097/01.mib.0000179467.01748.99.
    1. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative colitis in adults. Am J Gastroenterol. 2019 Mar;114(3):384–413. doi: 10.14309/ajg.0000000000000152.
    1. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's disease in adults. Am J Gastroenterol. 2018 Apr;113(4):481–517. doi: 10.1038/ajg.2018.27.
    1. Peyrin-Biroulet L, Loftus EV, Colombel J, Sandborn WJ. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011 Jan;17(1):471–478. doi: 10.1002/ibd.21417.
    1. Crohn's & Colitis Foundation. [2019-04-30].
    1. De Dombal FT, Watts JM, Watkinson G, Goligher JC. Local complications of ulcerative colitis: Stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J. 1966 Jun 11;1(5501):1442–1447. doi: 10.1136/bmj.1.5501.1442.
    1. Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: An updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013;19(4):789–799. doi: 10.1097/MIB.0b013e31828029c0.
    1. Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A, Chai C, Kim M, Diehl GE, Ajami NJ, Petrosino JF, Zhou XK, Schwartzman S, Mandl LA, Abramowitz M, Jacob V, Bosworth B, Steinlauf A, Scherl EJ, Wu HJ, Simpson KW, Longman RS. IgA-coated E. coli enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation. Sci Transl Med. 2017 Feb 08;9(376):1–27. doi: 10.1126/scitranslmed.aaf9655.
    1. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel J. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015 Sep;110(9):1324–1338. doi: 10.1038/ajg.2015.233.
    1. Colombel J, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. Effect of tight control management on Crohn's disease (CALM): A multicentre, randomised, controlled phase 3 trial. Lancet. 2018 Dec 23;390(10114):2779–2789. doi: 10.1016/S0140-6736(17)32641-7.
    1. Walsh A, Travis S. What's app? Electronic health technology in inflammatory bowel disease. Intest Res. 2018 Jul;16(3):366–373. doi: 10.5217/ir.2018.16.3.366.
    1. Atreja A, Otobo E, Ramireddy K, Deorocki A. Remote patient monitoring in IBD: Current state and future directions. Curr Gastroenterol Rep. 2018 Mar 07;20(2):6. doi: 10.1007/s11894-018-0611-3.
    1. Patil SA, Cross RK. Current landscape of telemedicine practice in inflammatory bowel disease. Inflamm Bowel Dis. 2018 Sep;24(9):1910–1917. doi: 10.1093/ibd/izy113.
    1. Kelso M, Feagins LA. Can smartphones help deliver smarter care for patients with inflammatory bowel disease? Inflamm Bowel Dis. 2018 Jun 08;24(7):1453–1459. doi: 10.1093/ibd/izy162.
    1. Arksey H, O'Malley L. Scoping studies: Towards a methodological framework. Int J Soc Res Methodol. 2005 Feb;8(1):19–32. doi: 10.1080/1364557032000119616.
    1. Levac D, Colquhoun H, O'Brien KK. Scoping studies: Advancing the methodology. Implement Sci. 2010 Sep 20;5:69. doi: 10.1186/1748-5908-5-69.
    1. Elkjaer M, Shuhaibar M, Burisch J, Bailey Y, Scherfig H, Laugesen B, Avnstrøm S, Langholz E, O'Morain C, Lynge E, Munkholm P. E-health empowers patients with ulcerative colitis: A randomised controlled trial of the Web-guided 'Constant-care' approach. Gut. 2010 Dec;59(12):1652–1661. doi: 10.1136/gut.2010.220160.
    1. Pedersen N, Thielsen P, Martinsen L, Bennedsen M, Haaber A, Langholz E, Végh Z, Duricova D, Jess T, Bell S, Burisch J, Munkholm P. eHealth: Individualization of mesalazine treatment through a self-managed Web-based solution in mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2014 Dec;20(12):2276–2285. doi: 10.1097/MIB.0000000000000199.
    1. Pedersen N, Elkjaer M, Duricova D, Burisch J, Dobrzanski C, Andersen NN, Jess T, Bendtsen F, Langholz E, Leotta S, Knudsen T, Thorsgaard N, Munkholm P. eHealth: Individualisation of infliximab treatment and disease course via a self-managed Web-based solution in Crohn’s disease. Aliment Pharmacol Ther. 2012 Nov;36(9):840–849. doi: 10.1111/apt.12043. doi: 10.1111/apt.12043.
    1. Ankersen DV, Carlsen K, Marker D, Munkholm P, Burisch J. Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease. J Gastroenterol Hepatol. 2017 Mar;32 Suppl 1:27–31. doi: 10.1111/jgh.13691.
    1. Carlsen K, Jakobsen C, Houen G, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Self-managed eHealth disease monitoring in children and adolescents with inflammatory bowel disease: A randomized controlled trial. Inflamm Bowel Dis. 2017 Mar;23(3):357–365. doi: 10.1097/MIB.0000000000001026.
    1. Atreja A, Khan S, Rogers JD, Otobo E, Patel NP, Ullman T, Colombel JF, Moore S, Sands BE, HealthPROMISE Consortium Group Impact of the mobile HealthPROMISE platform on the quality of care and quality of life in patients with inflammatory bowel disease: Study protocol of a pragmatic randomized controlled trial. JMIR Res Protoc. 2015 Feb 18;4(1):e23. doi: 10.2196/resprot.4042.
    1. Atreja A, Khan S, Rogers J, Ullman A, Grinspan A, Itzkowitz S, Maser E, Cohen B, Colombel JF, Sands B. Impact of real-world home-based remote monitoring on quality of care and quality of life in inflammatory bowel disease patients: One-year results of pragmatic randomized trial. J Crohns Colitis. 2017 Feb 01;11(Suppl 1):S362–S363. doi: 10.1093/ecco-jcc/jjx002.678. doi: 10.1093/ecco-jcc/jjx002.678.
    1. Atreja A, Otobo E, Szigethy E, Kohli A, Shroff H, Chang H, Rogers J, Ullman T, Cohen B, Itzkowitz S, Sands B. Improved quality of care and quality of life for IBD patients using mobile-based remote monitoring platform: A randomized control trial. Inflamm Bowel Dis. 2018 Feb;24(Suppl 1):S21–S22. doi: 10.1093/ibd/izy019.063.
    1. Atreja A, Szigethy E, Otobo E, Chang HL, Keefer L, Rogers J, Kohli A, Ullman TA, Marion JF, Cohen BL, Maser E, Itzkowitz S, Colombel JF, Sands BE. Improved quality of care and quality of life for IBD patients using the HealthPROMISE app: A randomized, control trial. Gastroenterology. 2018 May;154(6):S-6. doi: 10.1016/s0016-5085(18)30506-7.
    1. Atreja A, Otobo E, Chang H, Keefer L, Rogers J, Ullman T, Ramireddy K, Marion J, Deorocki A, Berde E, Zlatopolsky R, Kohli A, Choksi P, Itzkowitz S, Colombel J, Sands B. HealthPROMISE: Utilization of patient-reported outcomes to measure quality of life in inflammatory bowel disease. iProc. 2017 Sep 22;3(1):e28. doi: 10.2196/iproc.8452.
    1. Heida A, Dijkstra A, Muller Kobold A, Rossen JW, Kindermann A, Kokke F, de Meij T, Norbruis O, Weersma RK, Wessels M, Hummel T, Escher J, van Wering H, Hendriks D, Mearin L, Groen H, Verkade HJ, van Rheenen PF. Efficacy of home telemonitoring versus conventional follow-up: A randomized controlled trial among teenagers with inflammatory bowel disease. J Crohns Colitis. 2018 Mar 28;12(4):432–441. doi: 10.1093/ecco-jcc/jjx169.
    1. Dijkstra A, Heida A, van Rheenen PF. Exploring the challenges of implementing a Web-based telemonitoring strategy for teenagers with inflammatory bowel disease: Empirical case study. J Med Internet Res. 2019 Mar 29;21(3):e11761. doi: 10.2196/11761.
    1. de Jong MJ, van der Meulen-de Jong AE, Romberg-Camps MJ, Becx MC, Maljaars JP, Cilissen M, van Bodegraven AA, Mahmmod N, Markus T, Hameeteman WM, Dijkstra G, Masclee AA, Boonen A, Winkens B, van Tubergen A, Jonkers DM, Pierik MJ. Telemedicine for management of inflammatory bowel disease (myIBDcoach): A pragmatic, multicentre, randomised controlled trial. Lancet. 2017 Sep 02;390(10098):959–968. doi: 10.1016/S0140-6736(17)31327-2.
    1. de Jong M, van der Meulen-de Jong A, Romberg-Camps M, Degens J, Becx M, Markus T, Tomlow H, Cilissen M, Ipenburg N, Verwey M, Colautti-Duijsens L, Hameeteman W, Masclee A, Jonkers D, Pierik M. Development and feasibility study of a telemedicine tool for all patients with IBD: MyIBDcoach. Inflamm Bowel Dis. 2017 Apr;23(4):485–493. doi: 10.1097/MIB.0000000000001034.
    1. Aguas M, Del Hoyo J, Faubel R, Muñoz D, Domínguez D, Bastida G, Navarro B, Barrios A, Valdivieso B, Correcher M, Nos P. A Web-based telemanagement system for patients with complex inflammatory bowel disease: Protocol for a randomized controlled clinical trial. JMIR Res Protoc. 2018 Dec 21;7(12):e190. doi: 10.2196/resprot.9639.
    1. Del Hoyo J, Nos P, Faubel R, Muñoz D, Domínguez D, Bastida G, Valdivieso B, Correcher M, Aguas M. A Web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: Pilot randomized controlled trial. J Med Internet Res. 2018 Nov 27;20(11):e11602. doi: 10.2196/11602.
    1. Cross RK, Jambaulikar G, Langenberg P, Tracy JK, Collins JF, Katz J, Regueiro M, Schwartz DA, Quinn CC. TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD): Design and implementation of randomized clinical trial. Contemp Clin Trials. 2015 May;42:132–144. doi: 10.1016/j.cct.2015.03.006.
    1. Cross RK, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Collins JF, Katz J, Ghazi L, Patil SA, Quezada SM, Beaulieu D, Horst SN, Russman K, Riaz M, Jambaulikar G, Sivasailam B, Quinn CC. A randomized controlled trial of TELEmedicine for patients with Inflammatory Bowel Disease (TELE-IBD) Am J Gastroenterol. 2019 Mar;114(3):472–482. doi: 10.1038/s41395-018-0272-8.
    1. Abutaleb A, Buchwald A, Chudy-Onwugaje K, Langenberg P, Regueiro M, Schwartz DA, Tracy JK, Ghazi L, Patil SA, Quezada SM, Russman KM, Quinn CC, Jambaulikar G, Beaulieu DB, Horst S, Cross RK. Inflammatory bowel disease telemedicine clinical trial: Impact of educational text messages on disease-specific knowledge over 1 year. Inflamm Bowel Dis. 2018 Sep 15;24(10):2191–2197. doi: 10.1093/ibd/izy149.
    1. Walsh A. TrueColours: Real Time Data Collection in Patients With Ulcerative Colitis [doctoral thesis] Oxford, UK: University of Oxford; 2017. [2019-07-29]. .
    1. Cross RK, Cheevers N, Rustgi A, Langenberg P, Finkelstein J. Randomized, controlled trial of home telemanagement in patients with ulcerative colitis (UC HAT) Inflamm Bowel Dis. 2012 Jun;18(6):1018–1025. doi: 10.1002/ibd.21795.
    1. Cross RK, Finkelstein J. Feasibility and acceptance of a home telemanagement system in patients with inflammatory bowel disease: A 6-month pilot study. Dig Dis Sci. 2007 Feb;52(2):357–364. doi: 10.1007/s10620-006-9523-4.
    1. van Deen WK, van der Meulen-de Jong AE, Parekh NK, Muyshondt Y, Kane E, Eimers L, Inserra EK, Zand A, DiNicola CA, Bhatia S, Choi JM, Ha C, van Oijen MG, Esrailian E, Hommes DW. Remote monitoring of IBD disease activity using the mobile Health Index (mHI): A validation study. Gastroenterology. 2015 Apr;148(4 Suppl 1):S-446. doi: 10.1016/s0016-5085(15)31501-8.
    1. Carlsen K, Houen G, Jakobsen C, Kallemose T, Paerregaard A, Riis LB, Munkholm P, Wewer V. Individualized infliximab treatment guided by patient-managed eHealth in children and adolescents with inflammatory bowel disease. Inflamm Bowel Dis. 2017 Sep;23(9):1473–1482. doi: 10.1097/MIB.0000000000001170.
    1. Apple App Store. [2019-07-29]. GI Monitor by Vertical Health, LLC .
    1. ibd.care. Fort Lauderdale, FL: PRIME Education; [2019-05-02].
    1. Apple App Store. [2019-04-30]. MyIBD .
    1. Apple App Store. [2019-04-30]. Oshi: IBD Tracker & Magazine by Oshi Health, Inc .
    1. Bastable SB. Essentials Of Patient Education. 2nd edition. Burlington, MA: Jones & Bartlett Learning; 2017.
    1. Fox S. Pew Research Center. Washington, DC: Pew Internet & American Life Project; 2007. Oct 08, [2019-04-30]. E-patients with a disability or chronic disease
    1. Promislow S, Walker JR, Taheri M, Bernstein CN. How well does the Internet answer patients' questions about inflammatory bowel disease? Can J Gastroenterol. 2010 Nov;24(11):671–677. doi: 10.1155/2010/957264.
    1. Siegel CA. Embracing the Internet for progress in shared decision-making. Inflamm Bowel Dis. 2007 Dec;13(12):1579–1580. doi: 10.1002/ibd.20259.
    1. Azer SA, AlOlayan TI, AlGhamdi MA, AlSanea MA. Inflammatory bowel disease: An evaluation of health information on the Internet. World J Gastroenterol. 2017 Mar 07;23(9):1676–1696. doi: 10.3748/wjg.v23.i9.1676.
    1. van Mierlo T, Fournier R, Fedorak R. Don't forget the doctor: Gastroenterologists' preferences on the development of mHealth tools for inflammatory bowel disease. JMIR Mhealth Uhealth. 2015 Jan 21;3(1):e5. doi: 10.2196/mhealth.3987.
    1. Eaden JA, Abrams K, Mayberry JF. The Crohn's and Colitis Knowledge Score: A test for measuring patient knowledge in inflammatory bowel disease. Am J Gastroenterol. 1999 Dec;94(12):3560–3566. doi: 10.1111/j.1572-0241.1999.01536.x.
    1. Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice. Qual Life Res. 2008 Dec;17(10):1297–1302. doi: 10.1007/s11136-008-9379-5.
    1. Pittet V, Maillard MH, Simonson T, Fournier N, Rogler G, Michetti P. Differences in outcomes reported by patients with inflammatory bowel diseases vs their health care professionals. Clin Gastroenterol Hepatol. 2018 Nov 22;:1. doi: 10.1016/j.cgh.2018.11.029.
    1. Jones MP, Walter S, Faresjö Å, Grodzinsky E, Kjellström L, Viktorsson L, Talley NJ, Agreus L, Andreasson A. Gastrointestinal recall questionnaires compare poorly with prospective patient diaries for gastrointestinal symptoms: Data from population and primary health centre samples. Eur J Gastroenterol Hepatol. 2019 Feb;31(2):163–169. doi: 10.1097/MEG.0000000000001296.
    1. Dreesen E, Gils A. Pharmacodynamic monitoring of biological therapies in chronic inflammatory diseases. Ther Drug Monit. 2019 Apr;41(2):131–141. doi: 10.1097/FTD.0000000000000571.
    1. Yokomizo L, Limketkai B, Park KT. Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis. BMJ Open Gastroenterol. 2016;3(1):e000093. doi: 10.1136/bmjgast-2016-000093.
    1. Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017 Mar;15(3):385–392.e2. doi: 10.1016/j.cgh.2016.09.012.
    1. Lakatos PL. Prevalence, predictors, and clinical consequences of medical adherence in IBD: How to improve it? World J Gastroenterol. 2009 Sep 14;15(34):4234–4239. doi: 10.3748/wjg.15.4234.
    1. Cabana MD, Jee SH. Does continuity of care improve patient outcomes? J Fam Pract. 2004 Dec;53(12):974–980.
    1. Gray WN, Resmini AR, Baker KD, Holbrook E, Morgan PJ, Ryan J, Saeed SA, Denson LA, Hommel KA. Concerns, barriers, and recommendations to improve transition from pediatric to adult IBD care: Perspectives of patients, parents, and health professionals. Inflamm Bowel Dis. 2015 Jul;21(7):1641–1651. doi: 10.1097/MIB.0000000000000419.
    1. Sebastian S, Jenkins H, McCartney S, Ahmad T, Arnott I, Croft N, Russell R, Lindsay JO. The requirements and barriers to successful transition of adolescents with inflammatory bowel disease: Differing perceptions from a survey of adult and paediatric gastroenterologists. J Crohns Colitis. 2012 Sep;6(8):830–844. doi: 10.1016/j.crohns.2012.01.010.
    1. Batbaatar E, Dorjdagva J, Luvsannyam A, Savino MM, Amenta P. Determinants of patient satisfaction: A systematic review. Perspect Public Health. 2017 Mar;137(2):89–101. doi: 10.1177/1757913916634136.
    1. Naidu A. Factors affecting patient satisfaction and healthcare quality. Int J Health Care Qual Assur. 2009;22(4):366–381. doi: 10.1108/09526860910964834.
    1. Vranceanu A, Ring D. Factors associated with patient satisfaction. J Hand Surg Am. 2011 Sep;36(9):1504–1508. doi: 10.1016/j.jhsa.2011.06.001.
    1. Sitzia J, Wood N. Patient satisfaction: A review of issues and concepts. Soc Sci Med. 1997 Dec;45(12):1829–1843. doi: 10.1016/s0277-9536(97)00128-7.
    1. Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J. Telemedicine and mobile health technology are effective in the management of digestive diseases: A systematic review. Dig Dis Sci. 2018 Jun;63(6):1392–1408. doi: 10.1007/s10620-018-5054-z.
    1. Baars JE, Markus T, Kuipers EJ, van der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: Results from a patient-empowerment study. Digestion. 2010;81(2):113–119. doi: 10.1159/000253862.
    1. Khan S, Dasrath F, Farghaly S, Otobo E, Riaz MS, Rogers J, Castillo A, Atreja A, Health PROMISE Consortium Group Unmet communication and information needs for patients with IBD: Implications for mobile health technology. Br J Med Med Res. 2016;12(3):12119. doi: 10.9734/BJMMR/2016/21884.
    1. Quinn CC, Chard S, Roth EG, Eckert JK, Russman KM, Cross RK. The Telemedicine for patients with Inflammatory Bowel Disease (TELE-IBD) clinical trial: Qualitative assessment of participants' perceptions. J Med Internet Res. 2019 Jun 03;21(6):e14165. doi: 10.2196/14165.
    1. Maramba I, Chatterjee A, Newman C. Methods of usability testing in the development of eHealth applications: A scoping review. Int J Med Inform. 2019 Jun;126:95–104. doi: 10.1016/j.ijmedinf.2019.03.018.
    1. Loddo I, Romano C. Inflammatory bowel disease: Genetics, epigenetics, and pathogenesis. Front Immunol. 2015;6:551. doi: 10.3389/fimmu.2015.00551. doi: 10.3389/fimmu.2015.00551.
    1. Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD, Harbus MD, Christos PJ, Brown RP, Scherl EJ. The effect of breathing, movement, and meditation on psychological and physical symptoms and inflammatory biomarkers in inflammatory bowel disease: A randomized controlled trial. Inflamm Bowel Dis. 2015 Dec;21(12):2886–2896. doi: 10.1097/MIB.0000000000000568.
    1. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2015 Jan;37(1):47–55. doi: 10.1007/s00281-014-0454-4.
    1. Klasnja P, Hekler EB, Shiffman S, Boruvka A, Almirall D, Tewari A, Murphy SA. Microrandomized trials: An experimental design for developing just-in-time adaptive interventions. Health Psychol. 2015 Dec;34S:1220–1228. doi: 10.1037/hea0000305.
    1. auggi. augGI Technologies Inc; [2019-04-30].
    1. Selter A, Tsangouri C, Ali SB, Freed D, Vatchinsky A, Kizer J, Sahuguet A, Vojta D, Vad V, Pollak JP, Estrin D. An mHealth app for self-management of chronic lower back pain (Limbr): Pilot study. JMIR Mhealth Uhealth. 2018 Sep 17;6(9):e179. doi: 10.2196/mhealth.8256.
    1. Yang L, Freed D, Wu A, Wu J, Pollak J, Estrin D. Your activities of daily living (YADL): An image-based survey technique for patients with arthritis. Proceedings of the 10th European Alliance for Innovation (EAI) International Conference on Pervasive Computing Technologies for Healthcare; 10th European Alliance for Innovation (EAI) International Conference on Pervasive Computing Technologies for Healthcare; May 16-19, 2016; Cancun, Mexico. 2016. May 16, pp. 41–44.
    1. Pollak J, Adams P, Gay G. PAM: A photographic affect meter for frequent, in situ measurement of affect. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems; SIGCHI Conference on Human Factors in Computing Systems; May 7-12, 2011; Vancouver, BC. 2011. May 07, pp. 725–734.
    1. Ranjitkar P. Toilet lab: Diagnostic tests on smart toilets? Clin Chem. 2018 Jun 28;64(7):1128–1129. doi: 10.1373/clinchem.2018.286567.
    1. Wald C. Diagnostics: A flow of information. Nature. 2017 Nov 08;551(7679):S48–S50. doi: 10.1038/551S48a.
    1. Alm E, Turgeman Y, Ratti C. WIRED. 2014. Mar 21, [2019-04-30]. 'Smart toilets and sewer sensors are coming' .
    1. Haisma S, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, Muller Kobold AC, van Rheenen PF. Head-to-head comparison of three stool calprotectin tests for home use. PLoS One. 2019;14(4):e0214751. doi: 10.1371/journal.pone.0214751.
    1. Heida A, Knol M, Kobold AM, Bootsman J, Dijkstra G, van Rheenen PF. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017 Nov;15(11):1742–1749.e2. doi: 10.1016/j.cgh.2017.06.007.
    1. Vinding KK, Elsberg H, Thorkilgaard T, Belard E, Pedersen N, Elkjaer M, Marker D, Carlsen K, Burisch J, Munkholm P. Fecal calprotectin measured by patients at home using smartphones: A new clinical tool in monitoring patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016 Feb;22(2):336–344. doi: 10.1097/MIB.0000000000000619.
    1. Chung AE, Sandler RS, Long MD, Ahrens S, Burris JL, Martin CF, Anton K, Robb A, Caruso TP, Jaeger EL, Chen W, Clark M, Myers K, Dobes A, Kappelman MD. Harnessing person-generated health data to accelerate patient-centered outcomes research: The Crohn's and Colitis Foundation of America PCORnet Patient Powered Research Network (CCFA Partners) J Am Med Inform Assoc. 2016 May;23(3):485–490. doi: 10.1093/jamia/ocv191.
    1. Sossenheimer P, Yvellez O, Andersen MJ, Pearl TA, Jurdi KE, Rubin DB, Mayampurath A, Rubin DT. Wearable devices can predict disease activity in inflammatory bowel disease patients. Gastroenterology. 2019 May;156(6):S-111. doi: 10.1016/S0016-5085(19)37069-6. doi: 10.1016/S0016-5085(19)37069-6.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere